BioSpace News Archive

Business

Retrophin Provides Corporate Update and 2019 Outlook

Top-line readout of pivotal FORT Study in PKAN expected 3Q19

January 8, 2019
·
7 min read
Business

MD Anderson Cancer Center and Nanobiotix announce a large-scale, comprehensive clinical collaboration on NBTXR3

Collaboration will initially support nine new phase I/II clinical trials with Nanobiotix’s first-in-class agent NBTXR3 for use in treating six cancer types

January 8, 2019
·
3 min read
Deals

Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company

Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets

January 8, 2019
·
15 min read
Biotech Bay

Apollomics, Inc. (previously CBT Pharmaceuticals, Inc.) Raises $100 Million in Series B Financing

Financing will accelerate development of the Company’s cancer immunotherapy and targeted therapy programs

January 8, 2019
·
3 min read
Drug Development

STERNA BIOLOGICALS PREPARES FOR PHASE IIb CLINICAL PROGRAM WITH GATA-3 ANTAGONIST DRUG CANDIDATES SB010 IN ASTHMA AND SB012 IN ULCERATIVE COLITIS

Key preparatory steps to conduct phase IIb trials initiated, including CMC and regulatory activities in the EU and US

January 8, 2019
·
5 min read
Business

MD Anderson Cancer Center and 4D pharma collaborate to evaluate live biotherapeutics in solid tumors

The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D’s live biotherapeutic oncology pipeline across a range of cancer settings.

January 8, 2019
·
3 min read
EVOTEC INVESTS IN FINANCING ROUND OF EXSCIENTIA

$ 26 M FINANCING ROUND (SERIES B) INCLUDES CELGENE, GT HEALTHCARE CAPITAL PARTNERS AND EVOTEC

January 8, 2019
·
5 min read
FDA

FDA Approves Record-Breaking 59 Novel Drugs in 2018

Over the course of 2018, the FDA approved 59 different novel drugs that range for the treatment of various cancers, chronic obstructive pulmonary disease (COPD), traveler’s diarrhea, migraine headaches and more.

January 8, 2019
·
3 min read
·
Alex Keown
Drug Development

With Likely Approvals on the Way, Bluebird Bio Offers up Pricing Strategy for Gene Therapy

For a moment, simply contemplate the possible price: $2.1 million for a drug. It’s not just any drug, however. Cambridge, Mass.-based bluebird bio’s LentiGlobin is a gene therapy being evaluated for transfusion-dependent ß-thalassemia.

January 8, 2019
·
4 min read
·
Mark Terry
Drug Development

Karolinska Development’s portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin

Karolinska Development’s portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD).

January 8, 2019
·
2 min read